ASXL1 and acute myeloid leukemia: For example, in the presence of CCAAT/enhancer-binding protein alpha (CEBPA) mutations, the ASXL1-G643W variant accelerates AML progression and chemotherapy resistance by downregulating key leukemia-related pathways, including ribosome biosynthesis, regulation of DNA damage response via p53 mediators, and immune activation [42].